Company Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 06/03/2026 GMT			5-day change	1st Jan Change
0.2145 ^USD	+3.62%		-5.80%	-37.97%

12-02	Virax Biolabs Group Limited announced that it expects to receive $5 million in funding	CI
12-02	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025	CI

Business description: Virax Biolabs Group Limited

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Number of employees: 19

Sales by Activity: Virax Biolabs Group Limited

Fiscal Period: March	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Distribution of Diagnostics Test Kits and PPE Products	124K	-	8.56K	156K	6.33K

See all business segments

Geographical breakdown of sales: Virax Biolabs Group Limited

Fiscal Period: March	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United Kingdom	-	-	8.56K	156K	6.33K

See all geographic segments

Executive Committee: Virax Biolabs Group Limited

Manager	Title	Age	Since
James Foster CEO	Chief Executive Officer	40	31/12/2012
Nigel McCracken COO	Chief Operating Officer	61	31/08/2023

See VIRAX BIOLABS GROUP LIMITED governance

Composition of the Board of Directors: Virax Biolabs Group Limited

Director	Title	Age	Since
James Foster CHM	Chairman	40	31/12/2012
Evan Norton BRD	Director/Board Member	51	-
Nelson Haight BRD	Director/Board Member	61	-
Nigel McCracken BRD	Director/Board Member	61	-
Iain Miller BRD	Director/Board Member	-	28/07/2025

Composition of the Board of Directors

Shareholders: Virax Biolabs Group Limited

Name	Equities	%	Valuation
Armistice Capital LLC 11.1 %	823,909	11.1 %	233 166 $
James Foster 4.965 %	368,570	4.965 %	104 305 $
Nigel McCracken 0.3143 %	23,332	0.3143 %	6 603 $
XTX Topco Ltd. 0.2888 %	21,437	0.2888 %	6 067 $
Nelson Haight 0.2065 %	15,333	0.2065 %	4 339 $

List of VIRAX BIOLABS GROUP LIMITED shareholders

Company details: Virax Biolabs Group Limited

Virax Biolabs Group Ltd.

Bo'Ness Road Newhouse

ML1 5UH, Lanarkshire

http://www.viraxbiolabs.com

address Virax Biolabs Group Limited(VRAX)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VIRAX BIOLABS GROUP LIMITED	+3.62%	-5.80%	-84.23%	-96.76%	1.59M
LONZA GROUP AG	-2.02%	-5.97%	-11.64%	-10.60%	45.49B
BEONE MEDICINES AG	+2.79%	-5.01%	+17.18%	+26.18%	33.41B
CELLTRION, INC.	+0.47%	-10.90%	+17.49%	+52.87%	31.32B
IQVIA HOLDINGS INC.	-2.25%	-2.42%	-5.92%	-20.53%	29.29B
REVOLUTION MEDICINES, INC.	-1.24%	-3.55%	+150.89%	+294.55%	19.5B
ASCENDIS PHARMA A/S	+1.39%	+3.06%	+58.83%	+111.91%	14.77B
MEDPACE HOLDINGS, INC.	+0.26%	+4.17%	+44.47%	+134.63%	13.36B
EUROFINS SCIENTIFIC SE	-1.64%	-5.25%	+24.86%	+3.99%	13.22B
IONIS PHARMACEUTICALS, INC.	-1.49%	-8.76%	+115.30%	+104.25%	12.23B
Average	-0.01%	-3.90%	+32.72%	+60.05%	21.26B
Weighted average by Cap.	-0.42%	-4.59%	+30.87%	+56.30%